What Is Chronic Spontaneous Urticaria? Dermatologists Explain
Chronic spontaneous urticaria is an inflammatory skin disease that causes hives that last for at least six weeks. Derms ...
Medpage Today on MSN11d
For Your Patients: How Well Is Your Hives Treatment Working?
Is it working? Are your symptoms improving, staying the same, or getting worse? You may be asked to fill out a couple of ...
Pharmabiz15h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Medpage Today on MSN11d
Defining Treatment Success in Chronic Spontaneous Urticaria
With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...
Managed Healthcare Executive3d
FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Monthly Prescribing Reference2d
FDA to Review Resubmitted Dupilumab sBLA for Chronic Spontaneous Urticaria
The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.